Abstract
A series of novel N-4-piperazinyl ciprofloxacin-ester hybrids has been synthesized and the structures confirmed by1H and 13C NMR, FT-IR spectral data, and elemental analysis. The products have been tested in vitro for their antibacterial activity against six bacterial strains (MRSA, Staphylococcus epidermidis, Bacillus subtilis, Escherichia coli,Salmonella enterica, and Klebsiella pneumoniae) and have demonstrated good antibacterial activity with MIC values range 6.25–200 µg/mL. Antifungal and cytotoxic activities of the products have been tested against Candida kefyr and human leukemia K562 cell line, respectively. All compounds inhibit growth of K562 cells more efficiently than the parent ciprofoxacin in a dose- and duration-dependent way. Molecular docking studies performed for the compound 3i indicates that similarly to ciprofloxacin it can act as an inhibitor of S. aureus DNA gyrase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Chai, Y., Liu, M.L., Lv, K., Feng, L.S., Li, S.J., Sun, L.Y., Wang, S., and Guo, H.Y., Eur. J. Med. Chem., 2011, vol. 46, p. 4267. https://doi.org/10.1016/j.ejmech.2011.06.032
Feng, L., Lv, K., Liu, M., Wang, S., Zhao, J., You, X., Li, S., Cao, J., and Guo, H., Eur. J. Med. Chem., 2012, vol. 55, p. 125. https://doi.org/10.1016/j.ejmech.2012.07.010
Li, Q., Xing, J., Cheng, H., Wang, H., Wang, J., Wang, S., Zhou, J., and Zhang, H., Chem. Biol. Drug Des., 2015, vol. 85, p. 79. https://doi.org/10.1111/cbd.d.12395
De Souza, M.V., Mini Rev. Med. Chem., 2005, vol. 5, p. 1009. https://doi.org/10.2174/138955705774575246
Sharma, P.C., Kumar, R., Chaudhary, M., Sharma, A., and Rajak, H.,J. Enzyme Inhib. Med. Chem., 2013, vol. 28, p. 1. https://doi.org/10.3109/14756366.2011.611943
Foroumadi, A., Ghodsi, S., Emami, S., Najjari, S., Samadi, N., Faramarzi, M.A., Beikmohammadi, L., Shirazi, F.H., and Shafiee, A., Bioorg. Med. Chem. Lett., 2006, vol. 16, p. 3499. https://doi.org/10.1016/j.bmcl.2006.03.103
Fardeau, S., Dassonville-Klimpt, A., Audic, N., Sasaki, A., Pillon, M., Baudrin, E., Mullié, C., and Sonnet, P., Bioorg. Med. Chem., 2014, vol. 22, p. 4049. https://doi.org/10.1016/j.bmc.2014.05.067
Sabbah, D.A., Saada, M., Khalaf, R.A., Bardaweel, S., Sweidan, K., Al-Qirim, T., Al-Zughier, A., Halim, H.A., and Sheikha, G.A., Bioorg. Med. Chem. Lett., 2015, vol. 25, p. 3120. https://doi.org/10.1016/j.bmcl.2015.06.011
Marchese, A., Barbieri, R., Coppo, E., Orhan, I.E., Daglia, M., Nabavi, S. F., Izadi, M., Abdollahi, M., Nabavi, S.M., and Ajami, M., Crit. Rev. Microbiol., 2017, vol. 43, p. 668. https://doi.org/10.1080/1040841X.2017.1295225
Patel, N.B., Agravat, S.N., and Shaikh, F.M., Med. Chem. Res., 2010, vol. 20, p. 1033. https://doi.org/10.1007/s00044-010-9440-0
Guimaraes, A.C., Meireles, L.M., Lemos, M.F., Guimaraes, M.C.C., Endringer, D.C., Fronza, M., and Scherer, R., Molecules, 2019, vol. 24, p. 2471. https://doi.org/10.3390/molecules24132471
Mandal, S.M., Dias, R.O., and Franco, O.L., J. Med. Food, 2017, vol. 20, p.1031. https://doi.org/10.1089/jmf.2017.0017
Patel, J.B., Cockerill, F.R., and Bradford, P.A., Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25, 2015, vol. 35, p. 1.
ACKNOWLEDGMENTS
We gratefully acknowledge financial support from the Research Council of the University of Tabriz.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
No conflict of interest was declared by the authors.
Rights and permissions
About this article
Cite this article
Shahbazi, A., Mostafavi, H., Zarrini, G. et al. Novel N-4-Piperazinyl Ciprofloxacin-Ester Hybrids: Synthesis, Biological Evaluation, and Molecular Docking Studies. Russ J Gen Chem 90, 1558–1565 (2020). https://doi.org/10.1134/S1070363220080265
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1070363220080265